Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) will be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.49 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries Stock Up 0.5 %

TEVA stock opened at $14.06 on Tuesday. The company has a 50-day moving average of $13.63 and a two-hundred day moving average of $11.65. The stock has a market capitalization of $15.76 billion, a price-to-earnings ratio of -29.90, a price-to-earnings-growth ratio of 1.67 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. Teva Pharmaceutical Industries has a 52-week low of $7.09 and a 52-week high of $14.47.

Analyst Ratings Changes

TEVA has been the subject of several recent analyst reports. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $12.00 to $19.00 in a report on Monday, February 12th. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a report on Friday, March 8th. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price objective for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.78.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the transaction, the vice president now owns 1 shares in the company, valued at $13.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard D. Francis sold 74,530 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the transaction, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The disclosure for this sale can be found here. Insiders have sold a total of 358,972 shares of company stock valued at $4,739,820 over the last ninety days. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.